Besides the elevated prevalence of S1PR2-aAb and S1PR3-aAb in the group of SSc patients with PAH, there was also a higher share of patients suffering from lung fibrosis in these groups (S1PR2-aAb; 60.7% vs. 45.3%, S1PR3–aAb; 71.9% vs. 41.9%). This evidence concerns the gene S1PR2 and pulmonary fibrosis.